Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
Zacks' 7 Best Stocks
for July, 2013
FREE Report for Zacks.com
Visitors Only
Visitors Only
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
- Latest News
- Most Popular
- FED Front & Center Again
- Roundtable Top Picks of the Week
- RTI: Sector Strength Charts - Where's the Opportunity Now?
- Surging Financial ETFs Beating the Market
- Utility Industry Stock Outlook - June 2013
- 3 Japanese Stocks to Buy Now
- Your Next Stock Should Be Making New Highs
- Anatomy of Success: Stoneridge (SRI)
- RTI: What Will the Fed Do Wednesday?
- AWS 6/19: Will Bernanke Clarify Matters Today?
- PFP 6/19: Investors Bold in Wake of the Fed
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 06/19/2013
| Company Name | Symbol | %Change |
|---|---|---|
| LUMOS NETWOR | LMOS | 5.82% |
| SUPPORTCOM I | SPRT | 4.19% |
| E HOUSECHINA | EJ | 3.40% |
| INGLES MARKE | IMKTA | 3.18% |
| SUMITOMO MIT | SMFG | 3.15% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
FPMI: CardioPET Phase 2 Trials Initiated
Brian Marckx, CFA
2011 10-K Filed
FluoroPharma (FPMI) filed their 10-K for the fiscal year ending December 31, 2011 on March 16th. Operating expenses were approximately $870k and $3.4 million for the fourth quarter and full year respectively, compared to $380k and $890k for the year earlier periods.
Net loss to common (includes the $977k accrued preferred stock dividends expense) and EPS were $4.4 million and ($0.25) in 2011 compared to $954k and ($0.08) for 2012.
Cash used in operations was $2.3 million in 2011 including $711k in Q4. Cash balance at 12/31/2011 stood at $3.3 million, essentially flat from the end of Q3 and benefitting from approximately $940k in net proceeds raised from the sale of equity during the most recent quarter.
As there were no surprises in the 10-K and product development has been tracking our expectations, despite us making some relatively immaterial tweaks to our model following the year-end report, our outlook as well as $2.00 price target and Outperform recommendation all remain intact.
CardioPET Phase II Trials Initiated
CardioPET, being developed for the assessment of myocardial metabolism, is now entering phase II trials in the assessment of myocardial perfusion and fatty acid uptake in coronary artery disease patients. As we noted in our initiation report on FluoroPharma earlier this year, initiation of phase II trials for CardioPET would be a significant milestone as the agent is expected to be one of FPMI's first products to reach commercialization. If eventually approved by the FDA, CardioPET is expected to offer a better alternative to stress-testing, a very large and rapidly growing opportunity.
In early March FluoroPharma announced they signed a letter of intent with SGS Life Sciences to provide clinical research services for Phase II trials of CardioPET. The Belgian-based trial will be open label and designed to assess safety and performance of CardioPET compared to stress echocardiography, myocardial perfusion imaging (MPI) and angiography. The trial will be conducted at two sites in Belgium with results anticipated in 2H 2012 - which is inline with our previously expected timeline. Per the recent 10-K, enrollment is expected to consist of between 30 and 100 patients with known stable chronic coronary artery disease that can not undergo stress testing.
To view a free copy of our most recent research report on FPMI or subscribe to our daily morning email alert, visit Brian Marckx's coverage page at http://scr.zacks.com/.
Get the full on FPMI - FREE